Company Overview and News

3
TLR / Timberline Resources Corporation TIMBERLINE RESOURCES, INC. FORM 8-K (Current Report)

2018-06-13 sec.gov
Timberline Resources Corp UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TLR

43
Timberline Resources Announces High-Grade Gold and Silver Assay Results from the Oswego Trend, Eureka Project, Nevada

2018-06-12 accesswire
COEUR D'ALENE, ID / ACCESSWIRE / June 12, 2018 / Timberline Resources Corporation (OTCQB: TLRS; TSX-V: TBR) ("Timberline" or the "Company") announced today that results of surface rock chip sampling and geologic mapping have defined new, high-grade, gold exploration targets along the Oswego trend on its 23 square-mile Eureka property in Northern Nevada. The Oswego trend, which extends 5 km north-south, includes high-grade gold at the Road-Cut target, high-grade silver and gold at the Geddes- Bertrand target, and numerous additional untested targets.
ABX MUX.RTWI MUX TLRS TLR MUX ABX

3
TLR / Timberline Resources Corporation TIMBERLINE RESOURCES, INC. FORM 8-K (Current Report)

2018-05-30 sec.gov
Timberline Resources Corp UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TLR

4
TLR / Timberline Resources Corporation TIMBERLINE RESOURCES, INC. FORM 8-K (Current Report)

2018-05-14 sec.gov
Timberline Resources Corp UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TLR

5
Timberline Announces Second Quarter 2018 Financial Results

2018-05-12 accesswire
COEUR D'ALENE, ID / ACCESSWIRE / May 11, 2018 / Timberline Resources Corporation (OTCQB: TLRS; TSX-V: TBR) (''Timberline'' or the ''Company'') today announced consolidated financial results for its second fiscal year 2018 quarter which ended March 31, 2018. A summary of selected financial results is presented in the following table:
TLRS TLR

3
TLR / Timberline Resources Corporation TIMBERLINE RESOURCES CORP FORM 10-Q (Quarterly Report)

2018-05-11 sec.gov
Timberline Resources Corp. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM
TLR

3
TLR / Timberline Resources Corporation TIMBERLINE RESOURCES, INC. FORM 8-K (Current Report)

2018-05-09 sec.gov
Timberline Resources Corp UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TLR

5
Timberline Resources Closes Private Placement Financing

2018-05-09 accesswire
COEUR D' ALENE, ID / ACCESSWIRE / May 9, 2018 / Timberline Resources Corporation (OTCQB: TLRS; TSX-V: TBR) ("Timberline" or the "Company") announced that it has received final approval from the TSX Venture Exchange for its private placement and has closed its previously announced non-brokered private placement (the "Offering").
TLRS TLR

5
Timberline Resources Announces Private Placement Offering

2018-05-08 accesswire
COEUR D' ALENE, ID / ACCESSWIRE / May 7, 2018 / Timberline Resources Corporation (OTCQB: TLRS; TSX-V: TBR) ("Timberline" or the "Company") announced today that it has initiated a non-brokered US$500,000 private placement offering of Units of the Company at a price of US$0.08 per Unit, with an option to increase the offering by up to 20%, solely to persons who qualify as accredited investors (the "Offering") under Rule 506(b) of Regulation D promulgated by the SEC under the Securities Act of 1933, as amended (the "Securities Act").
TLRS TLR

3
TLR / Timberline Resources Corporation TIMBERLINE RESOURCES, INC. FORM 8-K (Current Report)

2018-04-24 sec.gov
Timberline Resources Corp UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K TLR

43
Timberline Resources Agrees to Acquire Battle Mountain Gold-Copper Property Interests

2018-04-23 accesswire
COEUR D' ALENE, ID / ACCESSWIRE / April 23, 2018 / Timberline Resources Corporation (OTCQB: TLRS; TSX-V: TBR) ("Timberline" or the "Company") announced today that it has agreed to acquire ownership interests in two Nevada gold-copper mineral properties located in the world-class Battle Mountain mining district from Americas Gold Exploration, Inc. ("AGEI").
ABX MUX.RTWI MUX TLRS TLR MUX ABX

4
TLR / Timberline Resources Corporation TIMBERLINE RESOURCES, INC. FORM 424B3 (Prospectus)

2018-04-13 sec.gov
Timberline Resources Corp. Filed Pursuant to Rule 424(b)(3) Registration No. 333-218289 TIMBERLINE RESOURCES CORPORATION
TLR

4
TLR / Timberline Resources Corporation TIMBERLINE RESOURCES, INC. FORM 424B3 (Prospectus)

2018-04-13 sec.gov
Timberline Resources Corp Filed Pursuant to Rule 424(b)(3) Registration No. 333-218289 Prospectus Supplement No. 1 (to Prospectus dated March 29, 2018)
TLR

3
TLR / Timberline Resources Corporation TIMBERLINE RESOURCES, INC. FORM 8-K (Current Report)

2018-04-04 sec.gov
Timberline Resources Corp UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
TLR

9
Timberline Resources Re-initiates Eureka Project Exploration and Relinquishes Talapoosa Property Option

2018-04-03 accesswire
COEUR D' ALENE, ID / ACCESSWIRE / April 3, 2018 / Timberline Resources Corporation (OTCQB: TLRS; TSX-V: TBR) ("Timberline" or the "Company") announces that it is refocusing its exploration efforts on advancing the Windfall and Lookout Mountain projects at its Eureka property, concurrent with relinquishing its option to acquire the Talapoosa project. Eureka is a district-scale exploration property in Nevada's prolific Battle Mountain - Eureka gold trend that hosts numerous world-class gold deposits.
MALRY TLRS TLR MALRF MIN

Related Articles

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

STML: Stemline Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Stemline Therapeutics was incorporated under the laws of the State of Delaware in August 2003. Stemline Therapeutics is a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and potentially commercializing innovative oncology therapeutics that target difficult to treat cancers. The company's clinical pipeline includes: SL-401, SL-801, and SL-701. SL-401 pivotal data; plans for registration and potential commercialization: SL-401 has completed a pivotal trial in patients with blastic plasmacytoid dendritic cell neoplasm, or BPDCN, and has successfully met the primary endpoint of the trial. SL-401 is a targeted therapy directed to the interleukin-3 receptor-a, or CD123. SL-401 was granted breakthrough therapy designation, or BTD, by the U.S. Food and Drug Administration, or FDA, for the treatment of patients with BPDCN. Based on the trial results and other data, the company expect to complete submission of a rolling Biologics License...

Silicon Investor Message Boards

This table lists all message boards related to TLR / Timberline Resources Corporation on message board site Silicon Investor.

Timberline Resources Tularik Inc. (TLRK)
TolerRx (TLRX) Tri-Link Resources
CUSIP: 887133106